Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib.

Tomas BuchlerMarie KopeckaAnezka ZemankovaMarkéta WiesnerováEva StreckovaAneta RozsypalovaBohuslav MelicharAlexandr PoprachIgor Richter

Published in: Targeted oncology (2021)

Significant and early skeletal muscle loss occurs during treatment with cabozantinib in a high proportion of patients and is associated with poor PFS.

Keyphrases

metastatic renal cell carcinoma
skeletal muscle
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
insulin resistance
type diabetes
metabolic syndrome
patient reported